Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Relatório do Fundo Global COVID-19: mortes por HIV, tuberculose e malária podem quase dobrar em 12 meses, a menos que ações urgentes sejam tomadas
  • USA - español
  • USA - English
  • USA - Français
  • India - English
  • Latin America - español
  • USA - Deutsch

The Global Fund Logo (PRNewsfoto/The Global Fund to Fight AIDS, )

News provided by

The Global Fund to Fight AIDS, Tuberculosis and Malaria

Jul 14, 2020, 09:32 ET

Share this article

Share toX

Share this article

Share toX

GENEBRA, 14 de julho de 2020 /PRNewswire/ -- Um novo relatório divulgado hoje pelo Fundo Global estima que os países afetados por HIV, tuberculose e malária precisam urgentemente de US$ 28,5 bilhões para proteger o progresso extraordinário conseguido na luta contra essas três doenças no mundo nas últimas duas décadas.

O relatório, Mitigating the Impact of COVID-19 on Countries Affected by HIV, Tuberculosis and Malaria (Atenuar o impacto do COVID-19 nos países afetados por HIV, tuberculose e malária), foi publicado hoje para destacar o impacto do COVID-19 e os recursos necessários para proteger o progresso contra o HIV, a TB e a malária - doenças que ainda matam mais de 2,4 milhões de pessoas por ano. Desde 2002, a parceria do Fundo Global ajudou a salvar mais de 32 milhões de vidas e a reduzir quase pela metade as mortes por HIV, tuberculose e malária desde o pico da epidemia. A pandemia do COVID-19 agora ameaça reverter esse progresso.

Além do número de vítimas do COVID-19, que poderia ser catastrófico nos países mais vulneráveis, as estimativas sugerem que as mortes por HIV, tuberculose e malária podem dobrar se os sistemas de saúde ficarem sobrecarregados, os programas de tratamento e prevenção forem interrompidos e os recursos forem desviados.

Globalmente, isso significa que o número anual de mortes por HIV, tuberculose e malária poderia voltar a níveis nunca vistos desde o auge da epidemia, acabando com quase duas décadas de progresso nas regiões mais atingidas.

"As apostas são extraordinariamente altas," disse Peter Sands, diretor executivo do Fundo Global. "Os efeitos indiretos do COVID-19 na luta contra o HIV, a tuberculose, a malária e outras doenças infecciosas poderiam ser catastróficos. Atenuar esse impacto exigirá ação rápida, níveis extraordinários de liderança e colaboração, além de importantes recursos extras. Acima de tudo, não devemos deixar ninguém para trás."

Para as comunidades mais pobres e vulneráveis já afetadas por HIV, tuberculose e malária, o COVID-19 representa uma forte ameaça. Elas não estão apenas muito vulneráveis ao COVID-19, mas também correm mais riscos com o HIV, a tuberculose e a malária. O impacto econômico do COVID-19 também recairá mais fortemente sobre essas comunidades, de modo que as deficiências nutricionais e o colapso dos serviços exacerbarão sua suscetibilidade às doenças.

Montar uma resposta eficaz ao COVID-19 e atenuar o impacto sobre o HIV, a tuberculose e a malária exigirá bem mais recursos do que os disponibilizados até o momento. O Fundo Global trabalhou com parceiros para estimar as prováveis necessidades nos países onde ele investe. Estimamos que serão necessários aproximadamente US$ 28,5 bilhões nos próximos 12 meses para adaptar os programas de HIV, tuberculose e malária para atenuar o impacto do COVID-19, treinar e proteger os profissionais de saúde, reforçar os sistemas de saúde para que não colapsem, e responder ao próprio COVID-19, principalmente por meio de testes, rastreamento e isolamento, e fornecer tratamentos assim que estiverem disponíveis (isso não inclui o custo de uma vacina).

O Fundo Global reagiu com firmeza ao surgimento do COVID-19, disponibilizando rapidamente até US$ 1 bilhão para apoiar os países que respondem à pandemia, adaptam seus programas de HIV, tuberculose e malária, e reforçam seus sistemas de saúde já sobrecarregados. No entanto, esses fundos serão quase totalmente utilizados até julho de 2020.

Levando em conta as contribuições de outros parceiros e o US$ 1 bilhão que o Fundo Global já comprometeu, o Fundo Global estima que precisaria de US$ 5 bilhões adicionais pelos próximos 12 meses para atenuar o impacto do COVID-19 nos países afetados por HIV, tuberculose e malária.

Manter o progresso contra as três doenças e combater a nova pandemia do COVID-19 exige uma ampla colaboração com governos, parceiros técnicos, sociedade civil, setor privado e comunidades. O Fundo Global é um parceiro fundador da parceria ACT-Accelerator para acelerar o desenvolvimento, a produção e o acesso igualitário aos testes, tratamento e vacinas do COVID-19. Estamos trabalhando em estreita colaboração com a OMS, o Banco Mundial, a Fundação para Novos Diagnósticos Inovadores (FIND), a UNICEF, os Centros para Controle e Prevenção de Doenças da África, Unitaid e outros parceiros na área de saúde na aquisição e implementação de testes de diagnóstico de COVID19, equipamento de proteção individual para profissionais de saúde e outros suprimentos essenciais, além do fortalecimento dos principais componentes dos sistemas de saúde.

Dado o papel do Fundo Global como o maior provedor multilateral de subsídios para a saúde do mundo e nosso foco no combate a doenças infecciosas e no fortalecimento dos sistemas de saúde, estamos em uma posição única para ajudar na resposta dos países à pandemia do COVID-19 e atenuar o impacto indireto sobre os tratamentos de HIV, tuberculose e malária.

Como na luta contra o HIV, a tuberculose e a malária, a resposta global ao COVID-19 deve trabalhar com comunidades e parceiros para proteger os direitos humanos e combater o estigma e a discriminação, especialmente entre populações centrais e vulneráveis.

"Para proteger e sustentar o progresso contra o HIV, a tuberculose e a malária, derrotar o COVID-19 e salvar vidas, precisamos nos unir para lutar," disse Sands.

Para ver o relatório completo, clique aqui.

Contato: 
Ibon Villelabeitia
+41-792-925-426

FONTE The Global Fund to Fight AIDS, Tuberculosis and Malaria

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED

Modal title

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.